JP6769962B2 - 癌治療のためのキナーゼ阻害剤プロドラッグ - Google Patents

癌治療のためのキナーゼ阻害剤プロドラッグ Download PDF

Info

Publication number
JP6769962B2
JP6769962B2 JP2017529818A JP2017529818A JP6769962B2 JP 6769962 B2 JP6769962 B2 JP 6769962B2 JP 2017529818 A JP2017529818 A JP 2017529818A JP 2017529818 A JP2017529818 A JP 2017529818A JP 6769962 B2 JP6769962 B2 JP 6769962B2
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
egfr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017529818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536408A (ja
JP2017536408A5 (enExample
Inventor
ボーン パターソン アダム
ボーン パターソン アダム
ブルース スメイル ジェフリー
ブルース スメイル ジェフリー
シルバ シェバン
シルバ シェバン
ポール ギーズ クリストファー
ポール ギーズ クリストファー
ロイ ブル マシュー
ロイ ブル マシュー
ジャクソン ビクトリア
ジャクソン ビクトリア
ピアース ティルマン
ピアース ティルマン
デイバー ニプン
デイバー ニプン
Original Assignee
オークランド ユニサービシーズ リミティド
オークランド ユニサービシーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オークランド ユニサービシーズ リミティド, オークランド ユニサービシーズ リミティド filed Critical オークランド ユニサービシーズ リミティド
Publication of JP2017536408A publication Critical patent/JP2017536408A/ja
Publication of JP2017536408A5 publication Critical patent/JP2017536408A5/ja
Application granted granted Critical
Publication of JP6769962B2 publication Critical patent/JP6769962B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017529818A 2014-12-03 2015-12-03 癌治療のためのキナーゼ阻害剤プロドラッグ Active JP6769962B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462087212P 2014-12-03 2014-12-03
US62/087,212 2014-12-03
US201562150729P 2015-04-21 2015-04-21
US62/150,729 2015-04-21
US201562167849P 2015-05-28 2015-05-28
US62/167,849 2015-05-28
US201562187750P 2015-07-01 2015-07-01
US62/187,750 2015-07-01
PCT/US2015/063806 WO2016090174A1 (en) 2014-12-03 2015-12-03 Kinase inhibitor prodrug for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2017536408A JP2017536408A (ja) 2017-12-07
JP2017536408A5 JP2017536408A5 (enExample) 2019-01-17
JP6769962B2 true JP6769962B2 (ja) 2020-10-14

Family

ID=56092487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529818A Active JP6769962B2 (ja) 2014-12-03 2015-12-03 癌治療のためのキナーゼ阻害剤プロドラッグ

Country Status (6)

Country Link
US (1) US10507210B2 (enExample)
EP (1) EP3226869A4 (enExample)
JP (1) JP6769962B2 (enExample)
CN (2) CN107427515B (enExample)
AU (1) AU2015358384B2 (enExample)
WO (1) WO2016090174A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
KR102323255B1 (ko) * 2017-02-15 2021-11-08 다이호야쿠힌고교 가부시키가이샤 의약 조성물
SG11202002060XA (en) 2017-09-08 2020-04-29 Univ Colorado Regents Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
US12280045B2 (en) 2017-09-08 2025-04-22 Taiho Pharmaceutical Co., Ltd. Antitumor agent and antitumor effect potentiator
ES2935729T3 (es) * 2017-09-14 2023-03-09 Lankenau Inst Medical Res Métodos y composiciones para el tratamiento del cáncer
WO2019125184A1 (en) * 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
KR20210066819A (ko) * 2018-09-04 2021-06-07 레인 세러퓨틱스 인코포레이티드 Her-유도 암을 치료 또는 예방하기 위한 화합물, 조성물 및 방법
WO2020084347A2 (en) * 2018-10-26 2020-04-30 Auckland Uniservices Combination of a kinase inhibitor and an immunotherapeutic agent, compositions and methods comprising the same
WO2020102304A1 (en) * 2018-11-13 2020-05-22 Rain Therapeutics Inc. Combination of a kinase inhibitor and an electrolyte, compositions and methods comprising the same
TW202039002A (zh) * 2018-12-07 2020-11-01 斯坦福大學托管董事會 缺氧標靶組成物及其與一parp抑制劑之組合以及此等的使用方法
MX2021010265A (es) * 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US6228575B1 (en) 1996-02-08 2001-05-08 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
BRPI0912170A2 (pt) * 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
AU2010221818A1 (en) 2009-03-11 2011-10-06 Auckland Uniservices Limited Prodrug forms of kinase inhibitors and their use in therapy
RU2568639C2 (ru) * 2009-09-02 2015-11-20 Окленд Юнисервисиз Лимитед Ингибиторы киназы, их пролекарственные формы и их применение в терапии
WO2011146945A2 (en) * 2010-05-21 2011-11-24 Cell Signaling Technology, Inc. Alk and ros kinase in cancer
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
EP2736895B1 (en) * 2011-07-27 2016-01-06 Astrazeneca AB 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
AU2013347962B2 (en) * 2012-11-21 2018-10-25 Janssen Biotech, Inc. Bispecific EGFR/c-Met antibodies
CN105073116A (zh) * 2013-03-14 2015-11-18 辉瑞大药厂 治疗非小细胞肺癌的egfr t790m 抑制剂与egfr 抑制剂的组合
EP2983591A4 (en) 2013-04-10 2016-12-28 Threshold Pharmaceuticals Inc PREDICTIVE AND RESPONSE BIOMARKERS FOR TH-302 CANCER THERAPY

Also Published As

Publication number Publication date
CN107427515A (zh) 2017-12-01
WO2016090174A1 (en) 2016-06-09
US20170360790A1 (en) 2017-12-21
EP3226869A1 (en) 2017-10-11
CN107427515B (zh) 2021-11-16
CN114224894B (zh) 2025-01-07
AU2015358384B2 (en) 2021-03-04
JP2017536408A (ja) 2017-12-07
EP3226869A4 (en) 2018-07-18
AU2015358384A1 (en) 2017-06-29
US10507210B2 (en) 2019-12-17
CN114224894A (zh) 2022-03-25

Similar Documents

Publication Publication Date Title
JP6769962B2 (ja) 癌治療のためのキナーゼ阻害剤プロドラッグ
JP2022071099A (ja) Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
US20170321281A1 (en) Methods and compositions for treatment of glioblastoma
WO2022020281A1 (en) Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent
CN107205933A (zh) Raf抑制剂与aurora激酶抑制剂的组合
BR112021011493A2 (pt) Terapia de combinação para tratamento de câncer
WO2013024865A1 (ja) Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法
TW202406552A (zh) 用於治療癌症之ｅｇｆｒ抑制劑
US20200316067A1 (en) Combination of raf inhibitors and taxanes
US12144813B2 (en) PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
US20260069596A1 (en) Use of plk1 inhibitor as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer
WO2025184410A1 (en) Treatment of nras-mutated metastatic colorectal cancer
KR20250092216A (ko) 소토라십으로 암을 치료하는 방법
TW202604516A (zh) 用嘧啶雜環化合物治療癌症
AU2022479909A1 (en) Sotorasib dosing regimen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200623

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200924

R150 Certificate of patent or registration of utility model

Ref document number: 6769962

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250